Biotech

Category / Pharmaceuticals & Biotech / Biotech

Critical Outcome Technologies Reports Successful Completion of Two-Species Toxicity Testing for COTI-2

LONDON, ONTARIO: Another critical milestone achieved as low toxicity confirmed in pre-IND testing ...

MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin''s(TM) Anti-Inflammatory BioTherapeutic Properties

CEDAR KNOLLS, NJ: Daily Use of Fortetropin Significantly Decreases Inflammatory Cytokine Levels; Company to Explore a Much Broader Range of Opportunities for Fortetropin as a Treatment Option for Inflammatory Condition ...

HTG Announces Completion of IVD Development and Supply Agreement With Illumina

TUCSON, AZ: ...

IlluminOss Medical Products Honored With Prize for Innovation by Deutsche Gesellschaft fur Unfallchirurgie (DGU) 2014

EAST PROVIDENCE, RI and BERLIN, GERMANY: Dr. Sascha Gick and Dr. Steffen Heck of St. Vinzenz-Hospital Koln Awarded for Outstanding Scientific Achievements With IlluminOss' Photodynamic Bone Stabilization System ...

RepliCel Submits Clinical Trial Application to Health Canada for Its Chronic Achilles Tendinosis Trial

VANCOUVER, BRITISH COLUMBIA: Autologous Cell Therapy, RCT-01, to Be Investigated for Treatment of Tendinopathies Refractory to Other Treatments ...

IBEX Reports Results for the Year Ended July 31, 2014

MONTREAL, QUEBEC: ...

Medivation Announces Participation at Upcoming Investor Conference

SAN FRANCISCO, CA: ...

Regen BioPharma''s Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies

SAN DIEGO, CA: Company Scientist Notes That One of the Major Side Effects Is the Destruction of Blood Vessels Leading to Internal Bleeding Which May Be Mitigated by Immunotherapeutic "Cocktail" ...

Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5

BUFFALO, NY: ...

Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP

NORWOOD, MA: ...

ProMetic''s Plasminogen IND and Clinical Program Cleared by FDA

ROCKVILLE, MARYLAND and LAVAL, QUEBEC: - Enrollment of Phase I patients to start in Q4 2014 - Agreement for the proposed Phase II/III clinical program to follow an accelerated approval pathway - First PPPS(TM) generated plasma-derived ther ...

ProMetic to Hold a Plasminogen Update Conference Call/Webcast

LAVAL, QUEBEC: ...

Compare Networks Names Steve Ernst Editor and General Manager of American Laboratory and Labcompare

SOUTH SAN FRANCISCO, CA: ...

Alchemia Announces Phase III Trial Results for HA-Irinotecan in Metastatic Colorectal Cancer

BRISBANE, AUSTRALIA: ...

Media Advisory: Free Public Lectures Featuring Jay Ingram

EDMONTON, ALBERTA: ...

Glythera Unveils ADC Cysteine Linker Technology

NEWCASTLE UPON TYNE, UNITED KINGDOM: ...

Critical Outcome Technologies Awards Stock Options

LONDON, ONTARIO: ...

Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology

SAN FRANCISCO, CA and YAVNE, ISRAEL: ...

Medivation Announces Third Quarter 2014 Financial Results Teleconference on November 6, 2014